Report error Found 97 Enz. Inhib. hit(s) with all data for entry = 7629
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 0.0500nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
3D Structure (crystal)TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 0.140nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 0.170nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 1.19nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 1.44nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 1.57nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 1.91nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 2.01nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 3.16nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 3.98nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 4.37nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 6.09nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 6.74nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 14.8nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 17.9nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 72.6nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 184nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 229nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKd: 240nMpH: 7.7Assay Description:HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) wer...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 241nM ΔG°: -35.1kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataIC50: 337nMT: 2°CAssay Description:To measure beta2-AR mediated inhibition of mitogenesis, HEK-beta2-AR, 1321N1 or U87MG cells were seeded in a 96-well plate at approximately 5,000 cel...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKd: 339nMpH: 7.7Assay Description:HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) wer...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 341nM ΔG°: -34.3kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 345nM ΔG°: -34.3kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKd: 347nMpH: 7.7Assay Description:HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) wer...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 474nM ΔG°: -33.6kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKd: 479nMpH: 7.7Assay Description:HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) wer...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKd: 1.78E+3nMpH: 7.7Assay Description:HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) wer...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 1.78E+3nM ΔG°: -30.5kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKd: 1.86E+3nMpH: 7.7Assay Description:HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) wer...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 1.86E+3nM ΔG°: -30.4kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 1.93E+3nM ΔG°: -30.3kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKd: 1.95E+3nMpH: 7.7Assay Description:HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) wer...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKd: 2.51E+3nMpH: 7.7Assay Description:HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) wer...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 2.54E+3nM ΔG°: -29.7kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 2.93E+3nM ΔG°: -29.4kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKd: 2.95E+3nMpH: 7.7Assay Description:HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) wer...More data for this Ligand-Target Pair
TargetBeta-1 adrenergic receptor(Rat)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 3.35E+3nM ΔG°: -29.0kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 3.70E+3nM ΔG°: -28.8kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKd: 3.72E+3nMpH: 7.7Assay Description:HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) wer...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKd: 5.25E+3nMpH: 7.7Assay Description:HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) wer...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 5.27E+3nM ΔG°: -28.0kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKd: 6.03E+3nMpH: 7.7Assay Description:HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) wer...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 6.04E+3nM ΔG°: -27.7kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 7.94E+3nM ΔG°: -27.1kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKd: 7.94E+3nMpH: 7.7Assay Description:HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) wer...More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 9.28E+3nM ΔG°: -26.7kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKd: 9.33E+3nMpH: 7.7Assay Description:HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) wer...More data for this Ligand-Target Pair
TargetBeta-1 adrenergic receptor(Rat)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKi: 1.02E+4nM ΔG°: -26.5kJ/molepH: 7.8 T: 2°CAssay Description:Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988)....More data for this Ligand-Target Pair
TargetBeta-2 adrenergic receptor(Human)
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
The United States of America, As Represented By The Secretary, Department of Health and Human Services
US Patent
Affinity DataKd: 1.02E+4nMpH: 7.7Assay Description:HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) wer...More data for this Ligand-Target Pair
